Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Campath-1H and DSG for Tolerance Induction in Renal Transplantation
NCT00001984Phase 2Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Nov 1999
- Primary completion
- Jun 2008
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab and deoxyspergualin in kidney transplant rejection, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoints: Number of Patients With Renal Allograft Rejection at 24 months, Rejection Day of Onset at 2 years and 1 more. Started Nov 1999; status: completed.
02
Drugs
alemtuzumabdeoxyspergualin
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00001984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001984.